Image of Four-Year Entecavir Therapy Reduces Hepatocellular Carcinoma, Cirrhotic Events, and Mortality in Chronic Hepatitis B Patients

LITERATURE

Four-Year Entecavir Therapy Reduces Hepatocellular Carcinoma, Cirrhotic Events, and Mortality in Chronic Hepatitis B Patients


Oral antiviral therapy may reduce the disease progression of chronic hepatitis B (CHB) patients. We aimed to further investigate the efficacy of long-term entecavir therapy in reduction the risk of hepatocellular carcinoma (HCC), cirrhotic events and mortality in a large group of CHB-related cirrhosis patients


Availability

REQJ538-05Titan CenterAvailable

Detail Information

Series Title
-
Call Number
-
Publisher : .,
Collation
-
Language
English
ISBN/ISSN
-
Classification
NONE
Content Type
-
Media Type
-
Carrier Type
-
Edition
-
Subject(s)
Specific Detail Info
-
Statement of Responsibility

Other version/related

No other version available


File Attachment



Information


RECORD DETAIL


Back To Previous